恩他卡朋添加治疗对药效减退的帕金森病患者的疗效观察  

Curative effects of Entacapone as adjunctive therapy for Parkinson disease patients with decreased pharmacodynamic

作　　者：于苏文[1] 郑秀琴[1] 陈红霞[1] 

机构地区：[1]解放军第102医院神经内科,常州213003

出　　处：《临床神经病学杂志》2010年第1期70-72,共3页Journal of Clinical Neurology

摘　　要：目的探讨恩他卡朋添加治疗对药效减退的帕金森病(PD)患者的疗效及安全性。方法对41例服用美多芭疗效减退的PD患者添加恩他卡朋治疗。在添加恩他卡朋治疗前和治疗后第l个月、2个月、3个月分别进行"统一PD评定量表(UPDRS)"评分及运动诱发电位(MEP)检查,比较各时间点美多芭的每日服用总量,并观察其不良反应。结果添加恩他卡朋治疗后第l个月、2个月、3个月UPDRSⅡ和UPDRSⅢ评分均较添加治疗前明显下降,差异有统计学意义(均P<0.05),美多芭每日服用总量也明显减少,与添加治疗前比较有统计学意义(均P<0.05);MEP静息阈值(RMT)在治疗后第3个月明显升高(P<0.05),潜伏期(CL)及皮质静息期(CSP)明显延长(均P<0.05);无严重不良反应。结论恩他卡朋添加治疗能有效改善美多芭药效减退PD患者的运动功能,且安全。Objective To investigate the curative effects and safety of Entaeapone as adjunctive therapy for Parkinson disease（PD）patients with decreased pharmacodynamic.Methods There were 41 PD patients who used to be treated with Madopar and the pharmacodynamic decreased.Entacapone was added to treat them.Unified Parkinson＇s Disease Rating Scale（UPDRS）and motor evoked potentials（MEP）were tested before and the 1st month,the 2nd month and the 3rd month after adding treatment.And the daily dosage of Madopar at those time spots were compares with each other.And the adverse reactions were analyzed.Results UPDRSⅡand UPDRSⅢ scores were decreased obviously at the 1st month,the 2nd month and the 3rd month after Entacapone adding treatment（all P〈0.05）.Madopar daily dosage was decreased significantly too（all P〈0.05）.At the 3rd month after treatment,MEP relaxed motor threshold elevated（P〈0.05）,and cortical latency and cortical silent period prolonged（all P〈0.05）.There was no severe adverse reaction appeared.Conclusion Entacapone as adjunctive therapy can improve the motor function of PD patients with decreased pharmacodynamic of Madopar,and it is safe.

关 键 词：恩他卡朋 美多芭 帕金森病 

分 类 号：R742.5[医药卫生—神经病学与精神病学]